3SBio Inc.
1530
Clasificación en acciones
#3688
Operating as an investment holding company, 3SBio Inc. specializes in the full... Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
Precio por acción
$1.83
Capitalización bursátil
$4.57B
Cambio (1 día)
-2.79%
Cambio (1 año)
-50.11%
País
CN
Comercio 3SBio Inc. (1530)
Categoría
Healthcare
Ganancias de 3SBio Inc. (1530)
Ganancias en Jun 2026 TTM: $1.53B
Secondo gli ultimi rapporti finanziari di 3SBio Inc., gli utili attuali della società sono $1.53B. Nel 2023, la società ha registrato un utile di $279.50M, una disminución en comparación con agli utili del 2022, che erano di $329.67M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de 3SBio Inc. desde 2012 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $1.53B | 310.18% |
| 2024 | $372.39M | 33.23% |
| 2023 | $279.50M | -15.22% |
| 2022 | $329.67M | 12.12% |
| 2021 | $294.02M | 96.17% |
| 2020 | $149.88M | -14.66% |
| 2019 | $175.64M | -19.22% |
| 2018 | $217.41M | 28.36% |
| 2017 | $169.38M | 38.34% |
| 2016 | $122.44M | 35.25% |
| 2015 | $90.53M | 55.68% |
| 2014 | $58.15M | 69.01% |
| 2013 | $34.41M | 64.53% |
| 2012 | $20.91M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | 245.34% |
US
|
|
| $-3.09B | -302.10% |
US
|
|
| $-4.02B | -362.93% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 27.71% |
NL
|
